核酸聚合物可有效靶向乙型肝炎表面抗原，但需要更多试验

StephenW

Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed
David Durantel∗,'Correspondence information about the author David DurantelEmail the author David Durantel
INSERM, U1052, Cancer Research Center of Lyon, Université de Lyon, Lyon, France
Tarik Asselah
Paris University, INSERM UMR 1149, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France
DOI: https://doi.org/10.1053/j.gastro.2020.04.020

Current treatments of chronically hepatitis B virus (HBV)-infected patients, based on nucleos(t)ide analogs (NAs) and/or pegylated-interferon-alfa (PEG-IFN),1, 2, 3, 4, 5 do not lead to a high rate of hepatitis B surface antigen (HBsAg)-loss/seroconversion (<10%).6 An increased therapy-induced HBsAg-loss is currently viewed as important to achieve higher functional cure rates.7,8 This loss, likely associated with a seroconversion to anti-HBsAg antibody (HBsAb), is hypothesized as instrumental for an immune response recovery, which would ensure long-term, off-treatment, control of the infection/disease.9,10 In this issue of Gastroenterology, Bazinet et al11 report on safety and efficacy results of 48-week treatments with 2 different HBsAg-targeting nucleic acid polymers (NAPs) REP-2139-Mg or REP-2165-Mg, combined with tenofovir-disoproxil-fumarate (TDF) and PEG-IFN.

StephenW

核酸聚合物可有效靶向乙型肝炎表面抗原，但需要更多试验
大卫·杜兰特尔（David Durantel）*，关于作者大卫·杜兰特尔（David Durantel）的通讯信息给作者大卫·杜兰特尔（David Durantel）发送电子邮件
INSERM，U1052，法国里昂大学里昂癌症研究中心
塔里克·阿瑟拉（Tarik Asselah）
巴黎大学，INSERM UMR 1149，AP-HPHôpitalBeaujon，法国克利希，肝病科
DOI：https：//doi.org/10.1053/j.gastro.2020.04.020

目前，基于核苷酸类似物（NAs）和/或聚乙二醇化干扰素-α（PEG-IFN）的慢性乙型肝炎病毒（HBV）感染患者的治疗方法1、2、3、4、5尚无导致乙型肝炎表面抗原（HBsAg）丢失/血清转化率较高（<10％）。6目前，治疗引起的HBsAg丢失增加对于实现更高的功能治愈率很重要。7,8可能与抗HBsAg抗体（HBsAb）血清转化有关，被认为是免疫应答恢复的工具，这将确保长期，非治疗性地控制感染/疾病[9,10]。 Bazinet等[11]报告了使用2种不同的靶向HBsAg的核酸聚合物（NAP）REP-2139-Mg或REP-2165-Mg联合替诺福韦-二甲磺酸-富马酸酯（TDF）和PEG-IFN。

StephenW

https://www.gastrojournal.org/ar ... 20)30493-5/fulltext